Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling

Journal of Biological Chemistry

Volumn 287, Issue 21, 2012, Pages 17530-17545

  Fonseca, Bruno D ^a,b   Diering, Graham H ^a,e   Bidinosti, Michael A ^b,f   Dalal, Kush ^a   Alain, Tommy ^b   Balgi, Aruna D ^a   Forestieri, Roberto ^a   Nodwell, Matt ^a   Rajadurai, Charles V ^b   Gunaratnam, Cynthia ^a   Tee, Andrew R ^c   Duong, Franck ^a   Andersen, Raymond J ^a   Orlowski, John ^d   Numata, Masayuki ^a   Sonenberg, Nahum ^b   Roberge, Michel ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d MCGILL UNIVERSITY   (Canada)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER CELLS; CANCER CELLS; CELL-FREE SYSTEM; CHEMICAL INHIBITION; COMPLEX 1; CONCENTRATION GRADIENTS; CYTOSOLS; IN-CONTROL; IN-VITRO; INHIBITORY EFFECT; KINASE ACTIVITY; MAMMALIAN TARGET; PARASITE-; PH BALANCE; PH HOMEOSTASIS; POTENTIAL MECHANISM; PROPIONIC ACIDS; SIGNALING CASCADES; STRUCTURAL FEATURE; STRUCTURE-ACTIVITY;

ANTIBIOTICS; CELLS; PH EFFECTS;

SIGNALING;

BICARBONATE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NICLOSAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROPIONIC ACID; PROTEIN KINASE B; PROTON;

ACIDIFICATION; ALKALINIZATION; ARTICLE; BINDING AFFINITY; BIOCATALYSIS; BREAST CANCER; CANCER CELL CULTURE; CELL FREE SYSTEM; CELL PH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DENSITY GRADIENT; DRUG MECHANISM; DRUG STRUCTURE; EMBRYO; IN VITRO STUDY; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTON TRANSPORT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEMATODAL AGENTS; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; MICE, KNOCKOUT; NICLOSAMIDE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

MAMMALIA; VERMES;

EID: 84861212263     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.359638     Document Type: Article

References (101)

1. Facchinetti, V., Ouyang, W., Wei, H., Soto, N., Lazorchak, A., Gould, C., Lowry, C., Newton, A. C., Mao, Y., Miao, R. Q., Sessa, W. C., Qin, J., Zhang, P., Su, B., and Jacinto, E. (2008) The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 27, 1932-1943
2. García-Martínez, J. M., and Alessi, D. R. (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416, 375-385
3. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (Pubitemid 40262113)
4. Hresko, R. C., and Mueckler, M. (2005) mTOR·RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280, 40406-40416 (Pubitemid 41780527)
5. Ikenoue, T., Inoki, K., Yang, Q., Zhou, X., and Guan, K. L. (2008) Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 27, 1919-1931
6. Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., and Sabatini, D. M. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev. Cell 11, 859-871 (Pubitemid 44804279)
7. Yan, L., Mieulet, V., and Lamb, R. F. (2008) mTORC2 is the hydrophobic motif kinase for SGK1. Biochem. J. 416, e19-21
8. Dowling, R. J., Topisirovic, I., Alain, T., Bidinosti, M., Fonseca, B. D., Petroulakis, E., Wang, X., Larsson, O., Selvaraj, A., Liu, Y., Kozma, S. C., Thomas, G., and Sonenberg, N. (2010) mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328, 1172-1176
9. Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., and Sabatini, D. M. (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. U.S.A. 95, 1432-1437 (Pubitemid 28103409)
10. Yu, Y., Yoon, S. O., Poulogiannis, G., Yang, Q., Ma, X. M., Villn, J., Kubica, N., Hoffman, G. R., Cantley, L. C., Gygi, S. P., and Blenis, J. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-1326
11. Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., Marto, J. A., and Sabatini, D. M. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-1322
12. Yea, S. S., and Fruman, D. A. (2011) Cell signaling. New mTOR targets Grb attention. Science 332, 1270-1271
13. Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., and Sawyers, C. L. (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U.S.A. 98, 10314-10319 (Pubitemid 32803017)
14. Kwiatkowski, D. J., Zhang, H., Bandura, J. L., Heiberger, K. M., Glogauer, M., el-Hashemite, N., and Onda, H. (2002) A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11, 525-534 (Pubitemid 34257489)
15. Kenerson, H. L., Aicher, L. D., True, L. D., and Yeung, R. S. (2002) Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 62, 5645-5650 (Pubitemid 35204715)
16. Onda, H., Crino, P. B., Zhang, H., Murphey, R. D., Rastelli, L., Gould Rothberg, B. E., and Kwiatkowski, D. J. (2002) Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol. Cell. Neurosci. 21, 561-574 (Pubitemid 36062714)
17. Corradetti, M. N., Inoki, K., Bardeesy, N., DePinho, R. A., and Guan, K. L. (2004) Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 18, 1533-1538 (Pubitemid 38868905)
18. Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., and Cantley, L. C. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91-99 (Pubitemid 38903165)
19. Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., and Cichowski, K. (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. U.S.A. 102, 8573-8578 (Pubitemid 40862777)
20. Huang, X., Wullschleger, S., Shpiro, N., McGuire, V. A., Sakamoto, K., Woods, Y. L., McBurnie, W., Fleming, S., and Alessi, D. R. (2008) Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 412, 211-221 (Pubitemid 351758227)
21. Sekulić, A., Hudson, C. C., Homme, J. L., Yin, P., Otterness, D. M., Karnitz, L. M., and Abraham, R. T. (2000) A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60, 3504-3513 (Pubitemid 30482170)
22. Fan, Q. W., Cheng, C., Knight, Z. A., Haas-Kogan, D., Stokoe, D., James, C. D., McCormick, F., Shokat, K. M., and Weiss, W. A. (2009) EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci. Signal. 2, ra4
23. Forbes, S. A., Bhamra, G., Bamford, S., Dawson, E., Kok, C., Clements, J., Menzies, A., Teague, J. W., Futreal, P. A., and Stratton, M. R. (2008) The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr. Protoc. Hum. Genet. Chapter 10, Unit 10.11
24. Sato, T., Nakashima, A., Guo, L., Coffman, K., and Tamanoi, F. (2010) Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 29, 2746-2752
25. Choi, J., Chen, J., Schreiber, S. L., and Clardy, J. (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273, 239-242 (Pubitemid 26285890)
26. Liang, J., Choi, J., and Clardy, J. (1999) Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 Å resolution. Acta Crystallogr. D Biol. Crystallogr. 55, 736-744 (Pubitemid 29194519)
27. Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., and Sabatini, D. M. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175 (Pubitemid 34876545)
28. Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., and Sabatini, D. M. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302 (Pubitemid 38991819)
29. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., and Yonezawa, K. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177-189 (Pubitemid 34876546)
30. Schalm, S. S., and Blenis, J. (2002) Identification of a conserved motif required for mTOR signaling. Curr. Biol. 12, 632-639 (Pubitemid 34315846)
31. Schalm, S. S., Fingar, D. C., Sabatini, D. M., and Blenis, J. (2003) TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 13, 797-806 (Pubitemid 36573247)
32. Yatscoff, R. W. (1996) Pharmacokinetics of rapamycin. Transplant. Proc. 28, 970-973
33. Hartford, C. M., and Ratain, M. J. (2007) Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin. Pharmacol. Ther. 82, 381-388 (Pubitemid 47414349)
34. Gibbons, J. J., Abraham, R. T., and Yu, K. (2009) Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin. Oncol. 36, Suppl. 3, S3-S17
35. Houghton, P. J. (2010) Everolimus. Clin. Cancer Res. 16, 1368-1372
36. Rizzieri, D. A., Feldman, E., Dipersio, J. F., Gabrail, N., Stock, W., Strair, R., Rivera, V. M., Albitar, M., Bedrosian, C. L., and Giles, F. J. (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 14, 2756-2762
37. Gingras, A. C., Raught, B., Gygi, S. P., Niedzwiecka, A., Miron, M., Burley, S. K., Polakiewicz, R. D., Wyslouch-Cieszynska, A., Aebersold, R., and Sonenberg, N. (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15, 2852-2864 (Pubitemid 33042055)
38. Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J. H., Hsu, P. P., Bagley, A. F., Markhard, A. L., and Sabatini, D. M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168
39. Guertin, D. A., and Sabatini, D. M. (2009) The pharmacology of mTOR inhibition. Sci. Signal. 2, pe24
40. Dowling, R. J., Topisirovic, I., Fonseca, B. D., and Sonenberg, N. (2010) Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim. Biophys. Acta 1804, 433-439
41. Yu, K., Toral-Barza, L., Shi, C., Zhang, W. G., Lucas, J., Shor, B., Kim, J., Verheijen, J., Curran, K., Malwitz, D. J., Cole, D. C., Ellingboe, J., Ayral-Kaloustian, S., Mansour, T. S., Gibbons, J. J., Abraham, R. T., Nowak, P., and Zask, A. (2009) Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 69, 6232-6240
42. García-Martínez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., and Alessi, D. R. (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 421, 29-42
43. Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., and Gray, N. S. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032
44. Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., and Shokat, K. M. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38
45. Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., James, D., Howard, Z., Dudley, P., Hughes, G., Smith, L., Maguire, S., Hummersone, M., Malagu, K., Menear, K., Jenkins, R., Jacobsen, M., Smith, G. C., Guichard, S., and Pass, M. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288-298
46. Fan, Q. W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., and Weiss, W. A. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341-349 (Pubitemid 43668732)
47. Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., Fabbro, D., Gabriel, D., Simonen, M., Murphy, L., Finan, P., Sellers, W., and García-Echeverría, C. (2008) Identification and characterization of NVPBEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863
48. Balgi, A. D., Fonseca, B. D., Donohue, E., Tsang, T. C., Lajoie, P., Proud, C. G., Nabi, I. R., and Roberge, M. (2009) Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 4, e7124
49. Díaz-Troya, S., Pérez-Pérez, M. E., Florencio, F. J., and Crespo, J. L. (2008) The role of TOR in autophagy regulation from yeast to plants and mammals. Autophagy 4, 851-865
50. Anand, N. (1997) Approaches to Design and Synthesis of Antiparasitic Drugs, p. 240, Elsevier, Amsterdam
51. Imming, P., Sinning, C., and Meyer, A. (2006) Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5, 821-834 (Pubitemid 44480536)
52. Fairweather, I., and Boray, J. C. (1999) Fasciolicides: efficacy, actions, resistance and its management. Vet. J. 158, 81-112 (Pubitemid 29460646)
53. Dunlop, E. A., Dodd, K. M., Seymour, L. A., and Tee, A. R. (2009) Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein-protein interactions for substrate recognition. Cell. Signal. 21, 1073-1084
54. 2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J. Biol. Chem. 276, 17914-17919
55. Dalal, K., and Duong, F. (2009) The SecY complex forms a channel capable of ionic discrimination. EMBO Rep. 10, 762-768
56. Baxter, K. A., and Church, J. (1996) Characterization of acid extrusion mechanisms in cultured fetal rat hippocampal neurones. J. Physiol. 493, 457-470 (Pubitemid 26187505)
57. Smith, M. A., and Ashford, M. L. (1998) Mode switching characterizes the activity of large conductance potassium channels recorded from rat cortical fused nerve terminals. J. Physiol. 513, 733-747 (Pubitemid 29008105)
58. Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., and Sabatini, D. M. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25, 903-915 (Pubitemid 46436534)
59. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I., Arthur, J. S., Alessi, D. R., and Cohen, P. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315
60. Bärlund, M., Monni, O., Kononen, J., Cornelison, R., Torhorst, J., Sauter, G., Kallioniemi, O. P., and Kallioniemi, A. (2000) Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res. 60, 5340-5344
61. Karni, R., de Stanchina, E., Lowe, S. W., Sinha, R., Mu, D., and Krainer, A. R. (2007) The gene encoding the splicing factor SF2/ASF is a protooncogene. Nat. Struct. Mol. Biol. 14, 185-193 (Pubitemid 46355578)
62. Wu, G. J., Sinclair, C. S., Paape, J., Ingle, J. N., Roche, P. C., James, C. D., and Couch, F. J. (2000) 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGMA1B genes. Cancer Res. 60, 5371-5375
63. Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., Gout, I., Downes, C. P., and Lamb, R. F. (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166, 213-223 (Pubitemid 38988774)
64. Shah, O. J., Wang, Z., and Hunter, T. (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14, 1650-1656 (Pubitemid 39239362)
65. Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., and Thomas, G. (2004) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431, 200-205 (Pubitemid 39243474)
66. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., and Pandolfi, P. P. (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193 (Pubitemid 40546387)
67. Fonseca, B. D., Alain, T., Finestone, L. K., Huang, B. P., Rolfe, M., Jiang, T., Yao, Z., Hernandez, G., Bennett, C. F., and Proud, C. G. (2011) Pharmacological and genetic evaluation of proposed roles of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK), extracellular signal-regulated kinase (ERK), and p90(RSK) in the control of mTORC1 protein signaling by phorbol esters. J. Biol. Chem. 286, 27111-27122
68. Fukunaga, R., and Hunter, T. (1997) MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J. 16, 1921-1933 (Pubitemid 27170953)
69. Waskiewicz, A. J., Flynn, A., Proud, C. G., and Cooper, J. A. (1997) Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 16, 1909-1920 (Pubitemid 27170952)
70. Waskiewicz, A. J., Johnson, J. C., Penn, B., Mahalingam, M., Kimball, S. R., and Cooper, J. A. (1999) Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol. Cell. Biol. 19, 1871-1880 (Pubitemid 29098245)
71. Pyronnet, S., Imataka, H., Gingras, A. C., Fukunaga, R., Hunter, T., and Sonenberg, N. (1999) Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J. 18, 270-279 (Pubitemid 29005042)
72. Ueda, T., Watanabe-Fukunaga, R., Fukuyama, H., Nagata, S., and Fukunaga, R. (2004) Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol. Cell. Biol. 24, 6539-6549 (Pubitemid 38944335)
73. Sonenberg, N. (2008) eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem. Cell Biol. 86, 178-183
74. Steinberg, G. R. (2009) Role of the AMP-activated protein kinase in regulating fatty acid metabolism during exercise. Appl. Physiol. Nutr. Metab. 34, 315-322
75. Hardie, D. G. (2004) The AMP-activated protein kinase pathway - new players upstream and downstream. J. Cell Sci. 117, 5479-5487
76. Zhang, L., He, H., and Balschi, J. A. (2007) Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration. Am. J. Physiol. Heart Circ. Physiol. 293, H457-H466 (Pubitemid 47105103)
77. McLaughlin, S. G., and Dilger, J. P. (1980) Transport of protons across membranes by weak acids. Physiol. Rev. 60, 825-863 (Pubitemid 10012303)
78. Terada, H. (1990) Uncouplers of oxidative phosphorylation. Environ. Health Perspect. 87, 213-218
79. Wang, G. J., Richardson, S. R., and Thayer, S. A. (1995) Intracellular acidification is not a prerequisite for glutamate-triggered death of cultured hippocampal neurons. Neurosci. Lett. 186, 139-144
80. Shih, T. M., Smith, R. D., Toro, L., and Goldin, A. L. (1998) High-level expression and detection of ion channels in Xenopus oocytes. Methods Enzymol. 293, 529-556 (Pubitemid 29342506)
81. + exchange. J. Gen. Physiol. 89, 185-213
82. Beauvoit, B., Rigoulet, M., Raffard, G., Canioni, P., and Guérin, B. (1991) Differential sensitivity of the cellular compartments of Saccharomyces cerevisiae to protonophoric uncoupler under fermentative and respiratory energy supply. Biochemistry 30, 11212-11220
83. Casey, J. R., Grinstein, S., and Orlowski, J. (2010) Sensors and regulators of intracellular pH. Nat. Rev. Mol. Cell Biol. 11, 50-61
84. Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., and Sabatini, D. M. (2010) Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141, 290-303
85. Han, J., and Burgess, K. (2010) Fluorescent indicators for intracellular pH. Chem. Rev. 110, 2709-2728
86. +-ATPase. Science 334, 678-683
87. Dröse, S., and Altendorf, K. (1997) Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. J. Exp. Biol. 200, 1-8 (Pubitemid 27058890)
88. Balgi, A. D., Diering, G. H., Donohue, E., Lam, K. K., Fonseca, B. D., Zimmerman, C., Numata, M., and Roberge, M. (2011) Regulation of mTORC1 signaling by pH. PLoS One 6, e21549
89. i changes through calcium flux, ERK1/2, p38, and PKC in bovine neutrophils. Vet. Immunol. Immunopathol. 115, 286-298
90. Brett, C. L., Donowitz, M., and Rao, R. (2005) Evolutionary origins of eukaryotic sodium/proton exchangers. Am. J. Physiol. Cell Physiol. 288, C223-C239 (Pubitemid 40105332)
91. Li, Y., Corradetti, M. N., Inoki, K., and Guan, K. L. (2004) TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci. 29, 32-38 (Pubitemid 38068478)
92. Pan, D., Dong, J., Zhang, Y., and Gao, X. (2004) Tuberous sclerosis complex: from Drosophila to human disease. Trends Cell Biol. 14, 78-85 (Pubitemid 38186641)
93. Becker, M. L., Remsen, E. E., Pan, D., and Wooley, K. L. (2004) Peptide-derivatized shell-cross-linked nanoparticles. 1. Synthesis and characterization. Bioconjug. Chem. 15, 699-709 (Pubitemid 38981943)
94. Zhang, H., Cicchetti, G., Onda, H., Koon, H. B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C. L., and Kwiatkowski, D. J. (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Investig. 112, 1223-1233 (Pubitemid 38056299)
95. Zhang, Y. J., Duan, Y., and Zheng, X. F. (2011) Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov. Today 16, 325-331
96. Chong, C. R., and Sullivan, D. J., Jr. (2007) New uses for old drugs. Nature 448, 645-646 (Pubitemid 47236844)
97. O'Connor, K. A., and Roth, B. L. (2005) Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat. Rev. Drug Discov. 4, 1005-1014
98. Chang, Y.-W., Yeh, T.-K., Lin, K.-T., Chen, W.-C., Yao, H.-T., Lan, S.-J., Wu, Y.-S., Hsieh, H.-P., Chen, C.-M., and Chen, C.-T. (2006) Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats. J. Food Drug Anal. 14, 329-333
99. Curnock, A. P., Thomson, T. A., Westwood, R., Kuo, E. A., Williamson, R. A., Yea, C. M., and Ruuthb, E. (2001) Inhibition of stimulated Jurkat cell adenosine 3′,5′-cyclic monophosphate synthesis by the immunomodulatory compound HR325. Biochem. Pharmacol. 61, 227-235 (Pubitemid 32121787)
100. Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., Pike, N. B., Strum, J. C., Steplewski, K. M., Murdock, P. R., Holder, J. C., Marshall, F. H., Szekeres, P. G., Wilson, S., Ignar, D. M., Foord, S. M., Wise, A., and Dowell, S. J. (2003) The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278, 11312-11319 (Pubitemid 36792688)
101. Korolchuk, V. I., Saiki, S., Lichtenberg, M., Siddiqi, F. H., Roberts, E. A., Imarisio, S., Jahreiss, L., Sarkar, S., Futter, M., Menzies, F. M., O'Kane, C. J., Deretic, V., and Rubinsztein, D. C. (2011) Lysosomal positioning coordinates cellular nutrient responses. Nat. Cell Biol. 13, 453-460